Oral steroids enhance epithelial repair in nasal polyposis via upregulation of the AP-1 gene network

C W Li,1 W Cheung,2 Z B Lin,3 T Y Li,3 J T Lim,4 D Y Wang1

ABSTRACT

Background: Chronic mucosal inflammation, epithelial damage and aberrant tissue remodelling are common features in nasal polyposis (NP). A study was undertaken to characterise the gene expression profile in NP tissues and to explore the molecular mechanisms underlying the ameliorative effects of glucocorticosteroids (GCs) in NP.

Methods: Two sets of NP biopsies (before and after GC treatment) were taken from 10 patients with untreated (GC-naïve) bilateral NP. Biopsy specimens of inferior turbinate from 6 patients who underwent surgery for nasal septal deviation served as nasal mucosal controls. DNA microarrays containing 38 500 genes were used to characterise the global gene expression profile. Functional network analysis was applied to identify the key molecular pathways and genes in response to GC treatment (GC-treated). Selected genes were retested by quantitative RT-PCR and immunohistochemistry in the same polyps and control samples.

Results: 64 genes were differentially expressed in GC-treated vs GC-naïve NP tissues. The highest scoring network was assembled around activation protein 1 (AP-1), a heterodimer of c-Fos and c-Jun oncoprotein, and five AP-1-related genes (COX-2, IL-6, AREG, HBEFG and EGR1) with tissue repair function. Quantitative PCR confirmed that AP-1 and its related genes were markedly repressed in GC-naïve polyps and were upregulated after GC treatment. Immunohistochemical staining indicated that epithelial restitution in GC-treated polyps was associated with increased expression of c-Jun protein.

Conclusions: Oral steroids promote epithelial repair in NP via upregulation of the AP-1 (especially c-Jun) network and its related genes.

Nasal polyposis (NP), a common chronic inflammatory disorder of the upper airways, is often associated with asthma and other respiratory diseases.1 The infiltration of various inflammatory cells, epithelial damage and expression of the Th2 cytokines are similar to the pathological profile of asthma. From this perspective, NP could therefore be regarded as a paradigm of chronic airway inflammation.2

The important features of NP are mucosal inflammation, epithelial damage followed by aberrant tissue repair and structural changes (remodelling).3 Inflammation in NP is characterised by the increased expression of multiple inflammatory genes regulated by proinflammatory transcription factors such as nuclear factor (NF)-κB and activator protein-1 (AP-1), which binds to and activates coactivator molecules that acetylate core histones and switch on gene transcription. Enhanced immune and inflammatory responses in NP are associated with tissue repair and remodelling in the target tissue and are related to disease severity. Recruited inflammatory cells and activated epithelial cells in NP are the major source of cytokines sustaining the inflammatory reaction and activation, proliferation of fibroblasts and myofibroblast differentiation.

Glucocorticosteroids (GCs) are the most effective anti-inflammatory therapy for NP.1 The ability of GCs to elicit an anti-inflammatory effect is mediated by suppressing the multiple inflammatory genes that are activated in NP, mainly by reversing histone acetylation of activated inflammatory genes through binding of glucocorticoid receptors to coactivators and recruitment of histone deacetylase 2 to the activated transcription complex.4 An inflammatory insult could lead to normal reconstruction or pathological remodelling. An important aspect of GCs is to promote tissue repair and remodelling in NP and asthma through transforming growth factor (TGF)-β and epidermal growth factor/epidermal growth factor receptor (EGF/EGFR) signalling pathways.5–7 Previous studies have shown that transcription factors, cytokines and growth factors also influence the wound healing process in airway tissues.7,8

Airway epithelial repair is a well co-ordinated process. Epithelial remodelling in NP is a complex process which includes migration, proliferation and differentiation of epithelial cells, involving groups of interacting molecules such as transcription factors, cytokines and growth factors in overlapping signalling networks. In this study we sought to characterise the genome-wide transcriptional profile within NP tissues. We also sought to explore the genome-wide interaction network and to identify significant functional modules perturbed in response to GC therapy by comparing dysregulation of functional modules in NP before and after oral GCs. Understanding the mechanism by which GCs restore the normal phenotypic appearance within the nasal cavity may yield clues to the pathobiology of NP and enable the development of novel treatments.

METHODS

Nasal tissues

Ten patients with NP with refractory nasal obstruction underwent functional endoscopic sinus surgery. Two sets of polyp biopsies were taken from the same patient (before (GC-naïve) and after (GC-treated) initiating treatment with oral prednisone (10 mg three times per day for 3–5 days). None of the patients had an upper respiratory infection nor had they taken any form of GCs or antibiotics for more than 3 months before the study. None of the subjects had a...
history of aspirin exposure or asthma. Cases were coded to provide confidentiality. The clinical characteristics, diagnosis and atopic status (determined by serum specific IgE levels) of the subjects were noted (table 1). Biopsy tissue from the inferior turbinate was taken from six control subjects who underwent surgery for nasal septal deviation. This tissue served as a nasal mucosal control. Fresh specimens were divided into two sections; one section was preserved with RNA later (Ambion, Austin, TX, USA) for gene expression profiling and the other section was fixed in formalin for histological evaluation.

Microarray study and ingenuity pathways analysis (IPA)
Total cellular RNA was isolated from nasal tissues with RiboPure Kit (Ambion). The concentration and integrity of the purified RNA was determined. cRNA was reversely transcribed using 1 μg total RNA. Synthesised cRNA was hybridised onto Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA, USA) and processed accordingly (http://www.affymetrix.com/Auth/support/downloads/manuals/expression_ever_manual.zip). The quality of the microarray data was assessed (https://support/downloads/manuals/data_analysis_fundamentals_manual.pdf). This led to the exclusion of two NP samples and one control sample for microarray study. A total of 54 000 probe sets, representing approximately 38 500 genes, was analysed. Details of the analysis are shown in the online supplement. Functional and network analysis were performed using ingenuity pathways analysis (IPA) tools (Ingenuity Systems, www.ingenuity.com). Complete information is available in the online supplement.

Quantitative PCR
Selective genes were validated with quantitative PCR by using ABI Prism 7000 Sequence Detection System (ABI Applied Biosystems, Foster City, CA, USA). Relative gene expression was calculated using the comparative $2^{-\Delta\Delta C_{T}}$ method with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a reference.

Histological evaluation
Paraffin sections of nasal biopsies were stained with haematoxylin and eosin and eosinophil infiltration and the epithelial integrity of the biopsies were evaluated. c-Jun and c-Fos proteins were stained with monoclonal antibodies (Dako A/S, Glostrup, Denmark) and evaluated using a semiquantitative scoring system. Detailed information is provided in the online supplement.

Table 1 Clinical characteristics of patients undergoing polypectomy surgery for nasal polyposis (NP) or inferior turbinectomy (IT) for septal deviation (SD)

<table>
<thead>
<tr>
<th>Code</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Atopy</th>
<th>c-Jun staining*</th>
<th>Epithelial damage†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Before treatment</td>
<td>After treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Before treatment</td>
<td>After treatment</td>
</tr>
<tr>
<td>NP1</td>
<td>37</td>
<td>F</td>
<td>NP</td>
<td>–</td>
<td>3</td>
<td>9</td>
</tr>
<tr>
<td>NP2</td>
<td>52</td>
<td>M</td>
<td>NP</td>
<td>+</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>NP3</td>
<td>18</td>
<td>M</td>
<td>NP</td>
<td>+</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>NP4</td>
<td>55</td>
<td>F</td>
<td>NP</td>
<td>+</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>NP5</td>
<td>32</td>
<td>M</td>
<td>NP</td>
<td>+</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>NP6</td>
<td>48</td>
<td>F</td>
<td>NP</td>
<td>+</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>NP7</td>
<td>34</td>
<td>M</td>
<td>NP</td>
<td>+</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>NP8</td>
<td>55</td>
<td>M</td>
<td>NP</td>
<td>+</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>NP9</td>
<td>30</td>
<td>M</td>
<td>NP</td>
<td>–</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>NP10</td>
<td>24</td>
<td>M</td>
<td>NP</td>
<td>+</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>IT1</td>
<td>26</td>
<td>M</td>
<td>SD</td>
<td>–</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>IT2</td>
<td>36</td>
<td>F</td>
<td>SD</td>
<td>–</td>
<td>9</td>
<td>NA</td>
</tr>
<tr>
<td>IT3</td>
<td>29</td>
<td>M</td>
<td>SD</td>
<td>–</td>
<td>9</td>
<td>NA</td>
</tr>
<tr>
<td>IT4</td>
<td>23</td>
<td>F</td>
<td>SD</td>
<td>+</td>
<td>9</td>
<td>NA</td>
</tr>
<tr>
<td>IT5</td>
<td>33</td>
<td>M</td>
<td>SD</td>
<td>–</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>IT6</td>
<td>37</td>
<td>M</td>
<td>SD</td>
<td>+</td>
<td>9</td>
<td>9</td>
</tr>
</tbody>
</table>

NA, not applicable.
*c-Jun staining is described in the online supplement; overall score obtained by multiplying the extent score (0–3) by the intensity score (0–3).
†Epithelium evaluation as described in the online supplement: 0, intact epithelium; 1, moderately damaged epithelium; 2, severely damaged epithelium.

Figure 1 Venn diagram showing overlapping of differentially expressed genes in glucocorticosteroid (GC)-naive nasal polyposis (NP) tissue vs nasal mucosal control, GC-treated NP tissue vs nasal mucosal control and GC-treated vs GC-naive NP tissue.
**Statistical analysis**

Power sample estimation suggested that a minimum of four biopsies in each study group were required to detect a twofold difference in gene expression with a 1% significance level and 90% power (data not published). We would therefore expect to detect a twofold difference in gene expression with \( p < 0.01 \) and with a 90% chance of avoiding a type II error. Median values of fold change of gene expression were analysed using SPSS Version 14 (SPSS, Chicago, Illinois, USA). The Wilcoxon matched pairs sign rank test was used to compare gene expression levels between GC-treated and GC-naïve NP tissue. The Mann–Whitney two-tailed test was performed to compare gene expression levels between NP tissues (either GC-treated or GC-naïve) and nasal mucosal controls. Spearman rank analysis was used to analyse the correlation between the gene expression levels assessed by microarray and those measured by quantitative PCR, and between fold change of c-Jun and other AP-1 related genes. The Fisher exact test was used to assess the protein expression of c-Jun and the epithelial integrity in NP tissues. \( p \) Values <0.05 were considered significant.

**RESULTS**

**Genome-wide transcriptional alterations**

Genome-wide transcriptional alterations were measured and analysed. Significant changes were detected in 2482 transcripts that were differentially expressed in GC-naïve NP tissues compared with nasal mucosal controls, while 1906 transcripts differed in relative expression in GC-treated NP tissues compared with nasal mucosal controls (data not shown). The difference in the relative intensities of all these transcripts was at least twofold. For GC-treated versus GC-naïve NP tissues, 103 differentially regulated transcripts were detected. After filtering the unmapped genes, genes with unknown gene ontology and genes with redundant probe identities, 1441 and 1115 genes were found to be differentially expressed in GC-naïve and GC-treated tissues, respectively, compared with nasal mucosal controls (fig 1). The expression of 64 genes was different in GC-treated NP tissue compared with GC-naïve NP tissue (fig 1 and table E1 in online supplement). Interestingly, among those 64 GC-responsive genes, most of them (\( n = 45, 70.3\% \)) were also differentially expressed in GC-naïve NP tissue compared with nasal mucosal controls.

**Integrated analysis of molecular pathways**

Sixty-four differentially expressed GC-responsive genes were further analysed using IPA into functional categories and pathways. Our results indicated that differentially expressed molecules regulate critical biological functions such as cell death (45 molecules, \( p = 5.58 \times 10^{-10} \)), cellular growth and proliferation (47 molecules, \( p = 4.45 \times 10^{-10} \)), cellular development (36 molecules, \( p = 1.51 \times 10^{-11} \)) and cellular movement (54 molecules, \( p = 1.94 \times 10^{-11} \); fig 2).

To further elucidate the global changes in NP tissue and its response to GC treatment, we sought to computationally decipher the principal networks involved. The specificity of the connections for each gene was calculated, as defined by the percentage of its direct connections to other genes showing significant transcriptional changes. Our global representation revealed concerted dysregulation of functional modules in NP tissue. Among four networks identified by IPA calculation, the AP-1 network had the top score (39). Notably, 18 of the 64 GC-responsive genes that were differentially expressed had at least one gene in the AP-1 pathway, underscoring its pivotal role in its responsiveness to GC therapy (see table E2 in the online supplement). At the level of interconnecting functional modules, two important AP-1 genes (c-Jun and c-Fos) were the prominent interaction partners (see fig 3 and fig E1 in the online supplement). In addition, evaluation of the AP-1 subnetwork regions revealed that a group of AP-1 related genes (COX-2, IL6, AREG, HBEFG and EGR1) were modulated in NP tissue by the administration of GCs (see table E2 in the online supplement).

**Quantitative PCR**

To verify the microarray results, the same starting materials were used for quantitative PCR measurements. Appropriate primers for the genes of interest and controls were used (see table E3 in online supplement). The PCR data for AP-1 and its related genes were comparable to the results generated by the microarray experiments (fig 4). The rank order and magnitude of the gene expression profile derived from quantitative PCR were in accordance with the microarray data. Two glucocorticoid receptor (GR) isoforms were also measured by quantitative PCR; GR\( \alpha \) mRNA was significantly decreased in NP tissue compared with control tissues and GR\( \beta \) mRNA was undetectable in all samples (data not shown).

We investigated the correlation among gene expression in GC-treated NP tissues. c-Jun mRNA was positively correlated with c-Fos and JunB mRNA \( (r = 0.924, p < 0.001 \) and \( r = 0.527, p = 0.003 \), respectively; fig 5A, B). Similarly, c-Jun gene expression was positively correlated with AP-1-related genes (COX-2, IL-6 and EGR1) in GC-treated NP tissues (COX-2, \( r = 0.527, p = 0.003 \); IL-6, \( r = 0.662, p = 0.03 \) and EGR1, \( r = 0.895, p = 0.001 \); fig 5A–C).

**Histological and immunohistochemical studies**

Significant epithelial damage was evident in 8 of 10 GC-naïve NP tissues (table 1). Subtle epithelial damage (ie, squamous metaplasia) was also detected in the other 2 patients (NP3 and NP8 in table 1). The decrease in eosinophil infiltration in

---

**Figure 2** Twelve significant functional annotations for gene sets differentially expressed in glucocorticoid (GC)-treated versus GC-naïve nasal polyposis (NP) tissues; \( p \) values for a given function were calculated by considering the number of functional analysis genes participating in that function and the total number of genes known to be associated with that function in the Ingenuity pathway knowledge base (IPKB). On the y axis, the significance is expressed as the exponent of the \( p \) value calculated for each function. The horizontal line represents the threshold \( (p = 0.05) \) of the significant level of the functions.
GC-treated NP tissue was considerable. In 8 of 10 GC-treated NP tissues, significant improvement in epithelium structure was observed (table 2). Improvement in epithelium structure (ie, absence of squamous metaplasia) was also evident in patients NP3 and NP8 after GC treatment. Immunohistochemical staining indicated that c-Jun protein was predominantly expressed in the epithelium. The c-Jun protein level was markedly lower in GC-naïve NP tissues than in GC-treated NP tissues (fig 6, table 2). Equally important, the c-Jun protein level was positively correlated to the epithelial integrity in both GC-naïve and GC-treated NP tissues (table 2). No difference was observed in the c-Fos protein level in GC-naïve NP tissue, GC-treated NP tissue and nasal mucosal controls (data not shown).

DISCUSSION
Airway epithelium remodelling may represent a repair response to pathological insults such as inflammation, allergens, mechanical damage and environmental pollutants. Oral GCs are currently the most effective anti-inflammatory medicines.
for the treatment of recurrent NP. This is the first in vivo study
to decipher the role of the AP-1 gene pathway and epithelial
remodelling in NP. The key findings are: (1) Epithelial damage is
an important feature of NP and a remarkable epithelial
restitution is observed after GC treatment; (2) AP-1 and its
related genes appear to be the key molecular network under-
lying wound healing in NP; (3) Epithelial c-Jun protein
expression is upregulated by oral steroid therapy and is
positively correlated with epithelium restitution in NP tissues.

AP-1 is a heterodimer of Fos and Jun oncoproteins. The most
abundant AP-1 heterodimer is c-Fos:c-Jun. AP-1 and its
related genes participate in the induction of a wide variety of pro-
inflammatory proteins, receptors and mediators. In this
respect, AP-1 induces a variety of growth-related genes (eg,
the EGF protein family), cytokines (eg, IL-6) and enzymes
(eg, PTGS2, known as COX-2). Recent evidence suggests a
causative relationship between AP-1 and epithelial remodelling
in airway diseases. The epithelial localisation suggests that
AP-1 may play an important role in the pathology of NP. We
found a significant low level of c-Jun and c-Fos mRNA
expression in GC-naïve NP tissues compared with nasal mucosal

Figure 4  Correlation between quantitative PCR and microarray results.
Fold changes were determined by means of PCR and microarray,
respectively. Correlations are shown for c-Fos, c-Jun, FosB, JunB, COX-
2, IL6, HB-EGF, AREG and EGR1.

Figure 5  Relationship between mRNA level of c-Jun vs (A) c-Fos, (B) JunB, (C) COX-2, (D) IL6 and (E) EGR1. Δ, fold change in the indicated gene in
an individual patient before vs after glucocorticosteroid treatment. Fold changes were determined by PCR.
controls. c-Jun mRNA and protein levels were increased after GC therapy in NP tissue. In this study, c-Fos mRNA was upregulated in GC-treated NP. Immunohistochemical staining suggests that GC treatment did not improve the c-fos protein level in extracted NP tissues. Our results are in disagreement with a previous report in which raised c-Fos protein levels were detected in NP tissue and steroid treatment decreased the c-Fos protein level but did not affect the c-Fos mRNA level in NP tissues.18 Induction of AP-1 in response to GC treatment is highly complex and may be cell type-specific.19 20 c-Fos protein was expressed in endothelial cells, lymphocytes, granulocytes and monocytes. Baraniuk et al have studied the c-Fos mRNA level using a qualitative rather than quantitative measurement.18 The c-Fos mRNA level was normalised by β-actin intensity band, which is not a reliable internal control for GC-treated nasal samples.17 c-Fos mRNA and protein expression may also be affected by broad alterations in post-transcriptional processes such as increased turnover of c-Fos protein, negative autoregulation of c-Fos expression and mutual degradation between activated GR and c-Fos.21 22 Other plausible explanations for the conflicting result include variable factors such as choice of different subjects, dosage and duration of GC treatment, different experimental protocols and tissue types used in the experiments.

The integrated analysis of multidimensional transcriptional data has proved informative. Our network analyses have identified a number of AP-1-related genes (COX-2, IL6, AREG, HBEGF and EGR1) which appeared to modulate airway epithelial remodelling. AP-1 induces transcription of COX-2 which is the key enzyme required for the conversion of arachidonic acid into prostaglandins (PGs). COX-2/PGE2 signalling regulates the epithelial remodelling process.24 Decreased COX-2/PGE2 has been associated with aspirin intolerance in patients with NP.25 We found an upregulation of COX-2 mRNA in NP tissues after oral GC treatment. Dworski et al have shown that treatment with prednisone upregulates COX-2 mRNA and protein levels in atopic subjects.26 IL-6 is an important AP-1-related gene. AP-1 induces IL-6 expression through the CRE binding region,27 while the IL-6-mediated signal pathway enhances c-Jun expression.28 Inhaled corticosteroid promotes IL6 production and favours respiratory epithelial cell remodelling in airway diseases.15 29 EGFR and its ligands (AREG and HBEGF) are direct AP-1 target genes.30 Activation of EGF/EGFR signalling leads to the induction of AP-1.14 17 The EGF/EGFR signalling pathway influences epithelial remodelling.3 6 In this study, mRNA levels of AREG and HBEGF were decreased in NP tissues and were upregulated by GC treatment. EGR1, another AP-1-related gene, induces c-Jun expression and triggers c-Jun/AP-1 activation.31 Steroid increases expression of EGR1.32 EGR1 signals through AP-1/EGF pathways and modulates epithelial remodelling.33

This study has several limitations that need to be rectified in future investigations. We recruited a relatively small number of NP and control subjects in this study. Follow-up studies are needed in a large number of patients to verify this important finding. Another potential shortcoming is the analysis of NP
versus nasal mucosal control. Since there are various cell types in nasal tissues, some of the findings may reflect the differences in the cellular make-up of the tissues. A further limitation of the current study is that the functional networks and their essential gene-gene interactions are deduced by an array modelling approach which is based on predetermined database knowledge and can only be considered as a source of hypotheses. Functional testing will therefore be needed for the rigorous evaluation of individual molecular interactions inferred by our database approach.

In conclusion, we have explored the molecular mechanisms underlying the pathogenesis of NP and their response to GC treatment. Our data suggest that AP-1 and its related gene network are central molecular effectors of epithelial damage and repair, which can be modulated by GC treatment. Our findings may contribute to a better understanding of the key molecular pathways implicated in the pathogenesis of NP. We hypothesise that these immunoregulatory and remodelling effects elicited by steroids might, at least in part, be mediated by the AP-1 gene network.

Acknowledgements: The authors thank Dr Shanti Wassner and Dr Li Yang for their assistance in real-time PCR work, and Wen Hong Mei and Dr Yang Yan for technical expertise in histological tissue processing and staining.

Funding: DYW is funded by grants (NMRC/039/1999 and NMRC/1162/2008) from the National Medical Research Council (NMRC) of Singapore.

Competing interests: None.

Ethics approval: Approval to conduct this study was obtained from the Institutional Review Board of the First Affiliated Hospital, Sun Yet-Sen University and the National University of Singapore.

REFERENCES

Oral steroids enhance epithelial repair in nasal polyposis via upregulation of the AP-1 gene network

C W Li, W Cheung, Z B Lin, T Y Li, J T Lim and D Y Wang

Thorax 2009 64: 306-312 originally published online January 21, 2009
doi: 10.1136/thx.2008.106096

Updated information and services can be found at:
http://thorax.bmj.com/content/64/4/306

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2009/03/12/64.4.306.DC1

References
This article cites 31 articles, 8 of which you can access for free at:
http://thorax.bmj.com/content/64/4/306#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Ear, nose and throat/otolaryngology (218)
- Inflammation (1020)
- Molecular genetics (211)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/